CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,531 enrolled
Drug / intervention
Gepotidacin +3 moredrug
Likely dose
Gepotidacin 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04020341
NCT04020341Phase 3Completed

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

GlaxoSmithKline·interventional·Posted Jul 16, 2019·Updated Jun 22, 2023

In Brief

A Phase 3 clinical trial evaluating Gepotidacin, Placebo matching nitrofurantoin, and 2 other interventions for Urinary Tract Infections. Completed, enrolled 1,531 participants across 103 sites in 12 countries.

Detailed Summary

The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Czechia, Germany, Greece, Hungary, India, Mexico, Romania, Slovakia, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJul 16, 2019
Enrollment StartOct 17, 2019
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.0 years ago

Interventions

Gepotidacindrug

Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.

Placebo matching nitrofurantoindrug

Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.

Nitrofurantoindrug

Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.

Placebo matching gepotidacindrug

Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.